← Back to patent-cliff list
Nilotinib Transdermal (KeifeRx)
Tier C — Watch / tradeNilotinib Transdermal (KeifeRx)
KeifeRx LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Bcr-Abl, DDR1
Indications (approved)：Lewy body dementia
Regional status
US
Phase II
2026-09-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nilotinib Transdermal (KeifeRx)?
Approved indications include: Lewy body dementia.
When does the Nilotinib Transdermal (KeifeRx) patent expire?
No public expiry year is available for Nilotinib Transdermal (KeifeRx) yet; this page updates once verified.
How do I get a quote for Nilotinib Transdermal (KeifeRx) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29